MedTrace Logo

A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML

NCT05341050 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2022-04-22

No results posted yet for this study

Summary

patients with Ph+ CML-CP who have been treated with second-generation TKIs (nilotinib, dasatinib) for at least 3 years and maintains MMR for at least 2 years, continue to be treated with halved dose for 12 months, and then stop for 12 months.

Conditions

  • MMR on 12 Month

Interventions

DRUG

TKI

halve dose of 2G-TKI for 12 months and then withdrawal for 12 months

Sponsors & Collaborators

  • xuna

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2025-12-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05341050 on ClinicalTrials.gov